Adverse drug reaction assessment of pembrolizumab in cervical cancer treatment: a real-world pharmacovigilance study using the FAERS database
This real-world pharmacovigilance study systematically characterizes pembrolizumab-associated AEs in cervical cancer, identifying high-signal events such as hematologic disorders, endocrine dysfunction, and dermatologic toxicities. These findings provide critical evidence for risk stratification and safety monitoring in clinical practice, emphasizing the need for organ-specific vigilance during the 3-6 months treatment window.
Authors
- Zhuo Zhou (ORCID: https://orcid.org/0000-0001-5862-9854)
- Mingyi Yang (ORCID: https://orcid.org/0000-0001-8640-9795)
- Shan Wang (ORCID: https://orcid.org/0000-0003-3396-5936)
- Ming Zhang (ORCID: https://orcid.org/0000-0002-6027-4594)
- Huiping Zhang (ORCID: https://orcid.org/0000-0002-4902-0104)
- Jie Ren (ORCID: https://orcid.org/0000-0001-8533-5253)
- Juan Wang
Institutions
- Northwest University (CN)
- Xi'an Honghui Hospital (CN)
- First Hospital of Xi'an (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1582050
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18